European Medicines Company Commences Evaluation of Novel Gene Remedy Candidate Etranacogene Dezaparvovec for Individuals with Hemophilia B
Advertising and marketing Authorization Software (MAA) for etranacogene dezaparvovec might be reviewed beneath accelerated evaluation